Moderna and Merck Announce Promising Trial Data for V940 in Combination with Keytruda in Treating High-Risk Melanoma After Complete Resectomy

After a three-year study, the combination of V940 and Keytruda demonstrated a durable benefit in recurrence-free and distant metastasis-free survival in patients with high-risk melanoma after complete resection.